AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 79(5), 2008, pp. 793-796
Copyright © 2008 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manarin, R.
Right arrow Articles by Revelli, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manarin, R.
Right arrow Articles by Revelli, S.
Related Collections
Right arrow Bacterial Infection
Right arrow Immunology

SHORT REPORT


Beneficial Effects of Benznidazole during an Infectious-based Situation of Systemic Inflammatory Response: Cecal Ligation and Puncture

Romina Manarin*, Emanuel Bottasso, Oscar Bottasso, Esteban Serra, AND Silvia Revelli
Instituto de Inmunología, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina; Instituto de Biología Molecular y Celular de Rosario (IBR)-CONICET, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina

 

ABSTRACT

We have shown that benznidazole (BZL), a drug used to treat Chagas disease, markedly reduced the production of pro-inflammatory cytokines and NO-derived metabolites in experimentally Trypanosoma cruzi–infected rats. Treatment with BZL exerted beneficial effects in a model of inflammation-based pathology like murine experimental endotoxemia. Based on these findings, we wished to ascertain the effect of BZL in a closer situation to sepsis: the cecal ligation and puncture (CLP) model in C57BL/6 mice. We analyzed clinical course, survival, circulating levels of inflammation-related compounds (NO, tumor necrosis factor [TNF]-{alpha}), and bacteriemia. Recipients of BZL, 25 mg/kg, had an increased survival rate at 24 hours after CLP, showing a better clinical situation and a significant reduction of TNF-{alpha} levels and bacteriemia, with respect to the other groups. BZL failed to inhibit in vitro bacterial growth, suggesting that these effects may be partly caused by the immunomodulatory effects of BZL.

Received March 6, 2008. Accepted for publication July 6, 2008.

Acknowledgments: The authors thank Dr. María Teresa Ronco for expert assistance and Dr. Stella Pezzotto for critical help with statistical analysis.

Financial support: This work was supported by grants from Agencia Nacional de Promoción Científica y Tecnológica (BID 1728/OC-AR PICT 17500), Argentina.

* Address correspondence to Romina Manarin, Instituto de Inmunologi, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe 3100, 2000 Rosario, Argentina. E-mail: r.manarin{at}yahoo.com.ar

Authors’ addresses: Romina Manarin, Emanuel Bottasso, Oscar Bottasso, and Silvia Revelli, Instituto de Inmunologia, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe 3100, 2000 Rosario, Argentina. Romina Manarin and Esteban Serra, Instituto de Biología Molecular y Celular de Rosario (IBR)-CONICET, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, 2100 Rosario, Argentina.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Tropical Medicine and Hygiene.